EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical impact of the CPT1A p.P479L ‘Arctic variant’: Evidence for benefit, risk, and gaps in understanding

Ching-Hsi Chuang, Bojana Rakic, Graham Sinclair, Daniel L Metzger, Sorcha A Collins, Hilary Vallance, Cheryl Rockman-Greenberg, Laura Arbour

Molecular Genetics and Metabolism · 2026-12 · 149 (4) · 110313

DOI: 10.1016/j.ymgme.2026.110313 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Genetics and Metabolism, 2026-12. Verfasst von Ching-Hsi Chuang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC V6H 3N1, Canada. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CPT1A encodes carnitine palmitoyltransferase 1A (CPT1A), a crucial rate-limiting enzyme in fatty acid metabolism. Facilitating the mitochondrial transport of long-chain fatty acids for β-oxidation, acetyl-CoA and ketone bodies are produced for subsequent ATP production. This process is vital during periods of low glucose availability, such as overnight fasting or strenuous exercise, when the body experiences high energy demands. Because CPT1A is widely expressed in various tissues, CPT1A variants that affect CPT1A enzymatic activity can lead to a wide spectrum of metabolic dysfunction and clinical manifestations. Among the CPT1A variants that alter CPT1A functional dynamics, CPT1A p.P479L is one of the most notable variants. The CPT1A c.1436C>T p.P479L (rs80356779) is a unique variant that is highly prevalent in Indigenous populations of northern Canada, coastal British Columbia, Alaska and Greenland. Its high frequency in these populations may be attributed to positive selection, conferring an adaptive advantage in Arctic regions and coastal British Columbia. However, under certain conditions and in combination with other genetic factors, CPT1A p.P479L may also contribute to health risks, highlighting its dual nature as both an adaptive survival trait and a potential health concern. This paradox has garnered increasing attention in both scientific and medical fields. While research on CPT1A p.P479L has gradually been increasing over the past two decades, a comprehensive review of current research findings is still lacking. This review article aims to summarize the state of research on the CPT1A p.P479L variant, explore its health implications, and discuss future research directions.

Schlagwörter

Stichwörter der Autor:innen

Arctic variantCPT1A p.P479LIndigenous peopleMetabolic variantPositive selectionß-oxidation

Autor:innen und Institutionen

  • Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
  • Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada; BC Children's Hospital Research Institute, Vancouver, BC V6H 3N1, Canada.
  • BC Children's Hospital Research Institute, Vancouver, BC V6H 3N1, Canada; Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  • School of Public Health and Social Policy, University of Victoria, Victoria, BC V8W 2Y2, Canada.
  • Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB R3A 1S1, Canada.
  • Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC V6H 3N1, Canada; BC Children's Hospital Research Institute, Vancouver, BC V6H 3N1, Canada. Electronic address: larbour@u…

Förderung

  • Canadian Institutes of Health Research

Zitieren

APA

Chuang, C. H., Rakic, B., Sinclair, G., Metzger, D. L., Collins, S. A., Vallance, H., Rockman-Greenberg, C., & Arbour, L. (2026). Clinical impact of the CPT1A p.P479L ‘Arctic variant’: Evidence for benefit, risk, and gaps in understanding. Molecular Genetics and Metabolism, 149(4), 110313. https://doi.org/10.1016/j.ymgme.2026.110313

Vancouver

Chuang CH, Rakic B, Sinclair G, Metzger DL, Collins SA, Vallance H, et al. Clinical impact of the CPT1A p.P479L ‘Arctic variant’: Evidence for benefit, risk, and gaps in understanding. Molecular Genetics and Metabolism. 2026;149(4):110313. doi:10.1016/j.ymgme.2026.110313

BibTeX
@article{Chuang2026,
  author = {Chuang, Ching-Hsi and Rakic, Bojana and Sinclair, Graham and Metzger, Daniel L and Collins, Sorcha A and Vallance, Hilary and Rockman-Greenberg, Cheryl and Arbour, Laura},
  title = {Clinical impact of the CPT1A p.P479L ‘Arctic variant’: Evidence for benefit, risk, and gaps in understanding},
  journal = {Molecular Genetics and Metabolism},
  year = {2026},
  volume = {149},
  number = {4},
  pages = {110313},
  doi = {10.1016/j.ymgme.2026.110313}
}
Kostenlos starten →